Trial of Deferiprone in Parkinson's Disease. David Devos , Julien Labreuche , Olivier Rascol , Jean-Christophe Corvol , Alain Duhamel , Pauline Guyon Delannoy , Werner Poewe , Yaroslau Compta , Nicola Pavese , Evžen Růžička , Petr Dušek , Bart Post , Bastiaan R Bloem , Daniela Berg , Walter Maetzler , Markus Otto , Marie-Odile Habert , Stéphane Lehericy , Joaquim Ferreira , Richard Dodel , Christine Tranchant , Alexandre Eusebio , Stéphane Thobois , Ana-Raquel Marques , Wassilios G Meissner , Fabienne Ory-Magne , Uwe Walter , Rob M A de Bie , Miguel Gago , Dolores Vilas , Jaime Kulisevsky , Cristina Januario , Miguel V S Coelho , Stefanie Behnke , Paul Worth , Klaus Seppi , Thavarak Ouk , Camille Potey , Céline Leclercq , Romain Viard , Gregory Kuchcinski , Renaud Lopes , Jean-Pierre Pruvo , Pascal Pigny , Guillaume Garçon , Ophélie Simonin , Jessica Carpentier , Anne-Sophie Rolland , Dag Nyholm , Christoph Scherfler , Jean-François Mangin , Marie Chupin , Régis Bordet , David T Dexter , Caroline Fradette , Michael Spino , Fernando Tricta , Scott Ayton , Ashley I Bush , Jean-Christophe Devedjian , James A Duce , Ioav Cabantchik , Luc Defebvre , Dominique Deplanque , Caroline Moreau The New England journal of medicine（2022）
摘要
In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).
更多 查看译文
关键词
deferiprone, parkinsons
AI 理解论文
溯源树
样例
